• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Alpha Tau Medical Ltd. - Ordinary Shares (NQ:DRTS)

    8.320 +0.240 (+2.97%)
    Streaming Delayed Price Updated: 11:44 AM EDT, Apr 23, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Alpha Tau Medical Ltd. - Ordinary Shares

    < Previous 1 2 3 4 Next >
    News headline image
    Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau to Present at Sidoti March Virtual Small Cap Conference
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    In today's session, these stocks are experiencing unusual volume. ↗
    In today's session, these stocks are experiencing unusual volume. 
    Via Chartmill
    News headline image
    Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium
    Pancreatic cancer multi-center clinical trial in U.S. is underway; patient recruitment expected to be completed by the end of Q1 2026 
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer
    - FDA approval marks Alpha Tau’s fifth simultaneous active U.S. IDE as the Company expands Alpha DaRT’s reach into recurrent prostate cancer - 
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Stock Rallies To 3-Month High On Smaller-Than-Feared Q1 Loss: Retail Sentiment Stays Bearish ↗
    The company’s stock surged to a three-month high following its Q1 report, progress in FDA-approved clinical trials, and a recent capital raise. 
    Via Stocktwits
    News headline image
    Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
    Investment comes at a pivotal moment for Alpha Tau, which is experiencing remarkable growth on multiple fronts, with four active U.S. trial approvals, expansion into multiple internal organ... 
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Q1 Virtual Investor Summit: On-Demand Presentations Now Live
    Via ACCESS Newswire
    News headline image
    Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Treats First Patient with Recurrent Lung Cancer
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
    -Trial to focus on particularly vulnerable subset of patients, following strong clinician interest in use of the Alpha DaRT in this patient population - 
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    DRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q2 2024 ↗
    DRTS stock results show that Alpha Tau Medical beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    News headline image
    Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    DRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q1 2024 ↗
    DRTS stock results show that Alpha Tau Medical beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    News headline image
    Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    DRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q4 2023 ↗
    DRTS stock results show that Alpha Tau Medical beat analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.